Nektar Therapeutics (NKTR) Stock Price

NKTRStock

$35.78−34.90%52W

Market Cap$1.22B

P/E—

PEG Ratio0.31

Div yield—

Beta1.37

NKTR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-65.87%

Price vs S&P 500 (4W)-45.14%

PEG Ratio0.31

VGM Score37.81

Book Value / Share (Quarterly)$26.46

P/TBV (Annual)2.92x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-15.67%

Cash Flow / Share (Quarterly)$-6.88

Price vs S&P 500 (YTD)-27.30%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)-284.39%

EPS (TTM)$-6.60

10-Day Avg Trading Volume1.40M

EPS Excl Extra (TTM)$-6.60

Revenue Growth (5Y)-18.43%

EPS (Annual)$-9.73

ROI (Annual)-107.25%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-327.61%

Cash / Share (Quarterly)$20.05

Revenue Growth QoQ (YoY)-9.34%

ROA (Last FY)-58.51%

Revenue Growth TTM (YoY)-27.15%

EBITD / Share (TTM)$-5.77

ROE (5Y Avg)-153.36%

Operating Margin (TTM)-257.80%

Cash Flow / Share (Annual)$-10.27

P/B Ratio1.35x

P/B Ratio (Quarterly)2.61x

Net Income / Employee (Annual)$-2,604,400

EV / Revenue (TTM)22.71x

Net Interest Coverage (TTM)-8.87x

ROA (TTM)-25.45%

EV / EBITDA (TTM)1.86x

EPS Incl Extra (Annual)$-9.73

Current Ratio (Annual)4.97x

Quick Ratio (Quarterly)9.71x

3-Month Avg Trading Volume1.12M

52-Week Price Return-34.90%

Revenue / Employee (TTM)$866,500

Tangible BV / Share (Quarterly)$1.15

P/S Ratio (Annual)22.12x

Asset Turnover (Annual)0.20x

52-Week High$109.00

Operating Margin (5Y Avg)-299.88%

EPS Excl Extra (Annual)$-9.73

CapEx CAGR (5Y)-34.68%

Tangible BV CAGR (5Y)2.06%

26-Week Price Return-55.97%

Quick Ratio (Annual)4.62x

13-Week Price Return-47.58%

Total Debt / Equity (Annual)0.70x

Current Ratio (Quarterly)10.42x

Enterprise Value$1.24B

Revenue / Share Growth (5Y)30.77%

Asset Turnover (TTM)0.09x

Book Value / Share Growth (5Y)-5.92%

Revenue / Employee (Annual)$876,700

Inventory Turnover (Annual)3.81x

Pretax Margin (Annual)-281.52%

Cash / Share (Annual)$12.06

3-Month Return Std Dev63.53%

Gross Margin (5Y Avg)76.67%

Net Income / Employee (TTM)$-2,464,200

ROE (Last FY)-182.65%

Net Interest Coverage (Annual)-7.77x

EPS Basic Excl Extra (Annual)$-9.73

P/FCF (TTM)1.16x

Receivables Turnover (TTM)163.36x

Total Debt / Equity (Quarterly)0.06x

EPS Incl Extra (TTM)$-6.60

Receivables Turnover (Annual)163.36x

ROI (TTM)-32.51%

P/S Ratio (TTM)22.38x

Pretax Margin (5Y Avg)-323.80%

Revenue / Share (Annual)$3.27

Tangible BV / Share (Annual)$2.29

Price vs S&P 500 (52W)-50.43%

Year-to-Date Return-15.37%

5-Day Price Return-10.19%

EPS Normalized (Annual)$-9.73

ROA (5Y Avg)-53.15%

Net Profit Margin (Annual)-297.07%

Month-to-Date Return-40.90%

Cash Flow / Share (TTM)$-1.50

EBITD / Share (Annual)$-8.24

Operating Margin (Annual)-253.66%

LT Debt / Equity (Annual)0.70x

ROI (5Y Avg)-95.22%

LT Debt / Equity (Quarterly)0.06x

EPS Basic Excl Extra (TTM)$-6.60

P/TBV (Quarterly)3.11x

P/B Ratio (Annual)9.57x

Inventory Turnover (TTM)3.81x

Pretax Margin (TTM)-280.49%

Book Value / Share (Annual)$4.41

Price vs S&P 500 (13W)-50.27%

Beta1.37x

P/FCF (Annual)1.74x

Revenue / Share (TTM)$1.65

ROE (TTM)-37.54%

52-Week Low$33.40

vGradeB

gGradeD

mGradeD

vgmGradeD

NKTR Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 13, 2026	-$1.93	-$1.23	+36.37%(+$0.70)
Q1 2026	May 7, 2026	-$1.56	-$1.82	-16.76%(-$0.26)
Q4 2025	Mar 12, 2026	-$2.47	-$1.78	+28.05%(+$0.69)
Q3 2025	Nov 6, 2025	-$2.61	-$1.87	+28.26%(+$0.74)
Q2 2025	Aug 7, 2025	-$3.12	-$2.78	+10.89%(+$0.34)

NKTR Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.31

4.29

4.22

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
NKTRNektar Therapeutics	B	D	D	22.4x	-27.1%	100.0%	—	$35.78
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company developing immunotherapy medicines in clinical development. Its pipeline includes REZPEG (NKTR-358), NKTR-422, NKTR-0165, and NKTR-255, among other candidates. The company focuses on discovering and developing novel therapeutics to address unmet medical needs in immunology.

NKTR Next Earnings Report

Report dateNov 12, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$2.11

Revenue estimate$10.40M

Also reporting on Nov 12, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

NKTR Insider Transactions

SellAug 18, 2026
ROBIN HOWARD W
Chief Executive Officer
Shares: 418Value: $30,088
SellAug 18, 2026
ZALEVSKY JONATHAN
Officer
Shares: 186Value: $13,388

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Companies in Related Industries

REXREX American Resources Corp.Industrial Chemicals
UANCVR Partners, LPAgricultural Chemicals
INBXInhibrx Biosciences, Inc. Common StockBiological Products
EPCEdgewell Personal Care CompanyCosmetics & Toiletries
CRONCronos Group Inc. Common SharePharmaceutical Preparations
TSHATaysha Gene Therapies, Inc. Common StockBiological Products
ECVTEcovyst Inc.Chemicals
ODDODDITY Tech Ltd. Class A Ordinary SharesCosmetics & Toiletries

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.2

Strong Buy

Consensus rating

52-Week Range

Low$33.40

High$109.00